Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.40 +0.88 (+0.57%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Uncovering Dividend Opportunities with NYSE:JNJ.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
3 Dow Stocks That Are No-Brainer Buys in June
The 30-component Dow Jones Industrial Average has three phenomenal deals hiding in plain sight. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Sleep Easy: 3 Safe Stocks That Won’t Have You Stressin’
Explore three safe stocks to buy with sharp fundamentals in pharmaceuticals, household products, and restaurants. 
Via InvestorPlace
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
Performance Comparison: Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
What the Options Market Tells Us About Johnson & Johnson
Via Benzinga
NYSE:JNJ: good value for what you're paying.
JOHNSON & JOHNSON (NYSE:JNJ) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
The 3 Most Undervalued Dow Stocks to Buy in June 2024
Some undervalued Dow stocks are starting to look timely as we enter the last month of the first half of 2024. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 Dividend Aristocrats to Scoop Up During Market Pullbacks in June
Since three dividend aristocrat stocks have rewarded shareholders for decades, buy them now for a worry-free retirement. 
Via InvestorPlace
Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial
The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged bankruptcy. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile. 
Via Benzinga
7 Overlooked Stocks That Belong in Every Portfolio
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks. 
Via InvestorPlace
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 Magnificent Dividend Stocks to Buy and Hold Forever
These dividend stocks are keepers for income investors. 
Via The Motley Fool
Boring Is Beautiful: 3 Blue-Chip Stocks to Buy and Hold Forever
Discover why boring blue-chip stocks like Johnson & Johnson, Sysco, and S&P Global can prove to be excellent long-term investments. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson Completes Acquisition of Shockwave Medical
From Johnson & Johnson
Via Business Wire
3 Sorry Biotech Stocks to Sell in May While You Still Can
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell. 
Via InvestorPlace
Why Sarepta Therapeutics Stock Is Rising Today
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Stocks That Could Be Easy Wealth Builders
These investment ideas should help you grow your portfolio with minimal effort. 
Via The Motley Fool
Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit
Be careful with these overvalued blue-chip stocks, each of which is trading at a high multiple relative to its peers. 
Via InvestorPlace
Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial
Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia. 
Via Benzinga
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
Exposures Economy Pension
HealthTech Heroes: 3 Medical Technology Stocks to Buy Before They Boom
With innovations constantly being developed in the healthcare space, investors should target these medical technology stocks. 
Via InvestorPlace
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
From Numab Therapeutics AG
Via GlobeNewswire
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
From Johnson & Johnson
Via Business Wire
10 Best Vanguard Funds to Buy Right Now
These 10 Vanguard stock ETFs can help you build a top-notch portfolio. 
Via The Motley Fool
Topics ETFs
7 Dividend Stocks That Could Soar After Q1 Earnings Reports
Take a look at the seven dividend stocks to buy if you are here for passive income and capital gains in the near-term. 
Via InvestorPlace
5 Magnificent Stocks Being Bought for Warren Buffett's $646 Million "Secret" Portfolio
Warren Buffett's secret portfolio contains 90 securities -- five of which are phenomenal businesses whose shares were purchased in the March-ended quarter. 
Via The Motley Fool
3 Dow Stocks to Buy on the Dip: May 2024
Looking for Dow stocks to buy on the dip can be a risky proposition but quite lucrative if done correctly. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.